Shanghai, China, April 12th, 2023—Alebund Pharmaceuticals (“Alebund” or the “Company”) announced that it has closed its Pre-C round financing, with close to RMB 200 million. Participants in this round include Yangzhou Guojin Investment, Jiangsu Dingxin Capital, Yangzhou Longchuan Holdings a leading international sovereign fund, Lilly Asia Venture, Quan Capital, 3H Health, Octagon Capital, and Verition Fund.
As an industry pioneer in developing innovative treatments for kidney disease, Alebund has built a team with extensive experience in renal R&D and is dedicated to advancing the portfolio for the global patients. Funds raised in this round will be used to advance the company’s R&D pipeline. Currently, Alebund has three Class I innovative drugs under Phase I, II and III clinical developments, respectively. Additional 1-2 in-house developed products are expected to enter clinical testing by 2024.
In the meantime, Alebund has secured an RMB 800 million syndicated bank loan credit. This loan will be deployed for the construction of the manufacturing facility in Yangzhou, Jiangsu to support the commercialization of the company’s small molecule products.
Dr. Gavin Xia, co-founder, chairman, and CEO of Alebund, said, “Since the company’s inception, Alebund’s R&D and operational capabilities have been validated and gained continuous strong recognition and support from our new and existing investors. The company will further enhance its organization to prepare for a successful product launch, benefiting the global renal patients. With the advancement of our pipeline, we will also initiate the IPO process very soon.”
About Alebund Pharmaceuticals
Alebund is a startup jointly incubated by a group of industry leaders in the field of nephrology in Shanghai in 2018. As a clinical-stage biopharmaceutical company, Alebund focuses on the discovery and development of novel therapies primarily for kidney diseases and their complications, as well as other chronic conditions. Alebund has built a diversified and balanced pipeline of drug candidates targeting a range of renal diseases, including chronic kidney disease (CKD)/dialysis complications, IgA nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease (ADPKD). Alehund’s pipeline comprises both small-molecule and biological assets.
礼邦医药完成近 2 亿元人民币 Pre-C 轮融资与 8 亿人民币银团授信
2023 年 4 月 12 日，中国上海——礼邦医药（Alebund Pharmaceuticals）宣布完成近 2 亿元人民币 Pre-C 轮融资。本轮参与方包括扬州国金投资、江苏鼎信资本、扬州龙川控股、某国际知名主权基金、礼来亚洲基金、泉创资本、三正健康投资、Octagon Capital、Verition Fund 等。
作为聚焦肾病新药研发的行业先行者，礼邦医药拥有一支经验丰富的研发团队，致力于多个拥有全球权益产品的开发。本轮募集资金将全部用于公司研发管线推进。目前，礼邦已有 3 个一类新药分别处于 Ⅰ、Ⅱ、Ⅲ 期临床研发阶段；在未来两年，预计还有 1-2 个自主研发的产品进入临床阶段。
与此同步，礼邦医药也完成了 8 亿人民币银团贷款的授信签约。这部分授信资金将保证礼邦医药在江苏扬州的小分子生产基地的顺利建设，配合公司未来产品商业化进程。
礼邦医药联合创始人、董事长兼首席执行官夏国尧博士表示：“自公司成立以来，礼邦的研发和运营能力已充分验证，并持续得到投资机构和金融机构的认可。公司将继续快速推动产品临床研发、产业化和商业化上市，使礼邦的新药能尽早惠及患者；与此同时，礼邦医药也会尽快启动公司 IPO 的进程，回报股东和各方机构的长期支持。”
2018 年初，礼邦医药由最顶尖的肾脏病领域行业领导者孵化于中国上海，目前是一家处于临床阶段的生物制药公司，主要致力于肾脏病以及其他相关慢性疾病的创新药物发现和开发，为慢性肾脏病及相关疾病患者提供更佳临床治疗方案。礼邦医药已经建立起了丰富且均衡的肾脏病新药产品管线，包括针对慢性肾病（CKD）/透析并发症、IgA 肾病、糖尿病肾病、常染色体显性多囊肾病（ADPKD）等产品，公司在研产品包括小分子药物和生物制剂。